The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of SHR-4685 in participants with advanced solid tumors.
Have fully understood this study and voluntarily signed the informed consent form, with good compliance and cooperation with follow-up;
Age 18-75 years, any gender;
Performance status ECOG score 0 or 1;
Expected survival time greater than 3 months;
Participants who have received any approved anti-tumor drugs (including investigational anti-tumor drugs) within 4 weeks prior to the first dose of the IP;
Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 or to the level specified in the inclusion/exclusion criteria;
Presence of central nervous system (CNS) metastases;
Concurrent active malignancy other than the primary tumor;